Effect of Aspirin on Disability-free Survival in the Healthy Elderly
Author(s) -
John J. McNeil,
Robyn L. Woods,
Mark Nelson,
Christopher M. Reid,
Brenda Kirpach,
Rory Wolfe,
Elsdon Storey,
Raj C. Shah,
Jessica E. Lockery,
Andrew Tonkin,
Anne B. Newman,
Jeff D. Williamson,
Karen L. Margolis,
Michael E. Ernst,
Walter P. Abhayaratna,
Nigel Stocks,
Sharyn M. Fitzgerald,
Suzanne G. Orchard,
Ruth E. Trevaks,
Lawrence J. Beilin,
Geoffrey A. Donnan,
Peter Gibbs,
Colin I. Johnston,
Joanne Ryan,
Barbara Radziszewska,
Richard H. Grimm,
Anne M. Murray
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1800722
Subject(s) - aspirin , medicine , placebo , dementia , hazard ratio , clinical endpoint , gerontology , randomized controlled trial , physical therapy , disease , confidence interval , alternative medicine , pathology
Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom